At the Asembia AXS26 Summit in Las Vegas, Clarivate’s Dee Chaudhary warned that recent U.S. policy changes—most notably the Inflation Reduction Act, MFN pricing pressures, and the One Big, Beautiful Bill Act—are rapidly reshaping payer behavior, tightening utilization management, and creating new volatility for high‑cost specialty therapies.
The Asembia AXS26 Summit brought together senior executives from biopharma, payers, and consulting firms to assess how a confluence of legislative actions is redefining the economics of specialty drugs in the United States. Dee Chaudhary, principal of Commercial Strategy Consulting at Clarivate, argued that policy design has moved from theory to “real‑world math,” forcing manufacturers to rethink pricing, launch sequencing, and value narratives.
IRA‑driven price anchors: The first Medicare‑negotiated prices, effective January 2026, are already being used by payers and pharmacy benefit managers (PBMs) as de‑facto reference points. This creates a commercial floor that erodes manufacturers’ pricing leverage and may spill over into commercial markets beyond Medicare.
Accelerated utilization management: Payers are deploying tighter formularies, more prior authorizations, and step‑edit requirements faster than the statutory language of the Inflation Reduction Act anticipated. The shift is especially acute for high‑cost oncology and immunology products, where financial exposure is greatest.
Policy‑driven market volatility: The One Big, Beautiful Bill Act (OBBBA) and looming Medicare Part A solvency concerns are increasing coverage churn and affordability risk. Frequent plan switches disrupt patient adherence and make demand forecasting a moving target for both manufacturers and payers.
MFN and international reference pricing pressure: Emerging MFN‑style provisions are pulling U.S. prices toward global benchmarks. Manufacturers now face a narrowing “pricing corridor” where low‑price launches risk MFN tail exposure, while high‑price launches invite earlier, stricter utilization controls.
Strategic adaptation required: Continuous policy monitoring, scenario‑based pricing analytics, and earlier alignment of global launch sequencing with U.S. access realities are essential to maintain asset value and market access.
Chaudhary emphasized that the IRA’s pricing provisions are no longer hypothetical. With negotiated Medicare prices now live, PBMs treat these figures as baseline expectations in contract negotiations. This “commercial floor” influences not only Medicare Advantage and Part D plans but also commercial contracts, reshaping the pricing landscape across the board.
Financial risk is shifting onto health plans, prompting payers to adopt “friction‑based management.” The result is a rapid rollout of restrictive formularies, expanded prior‑authorization requirements, and step edits—particularly for specialty oncology and immunology therapies. Some plans have even replaced legacy benefit designs with more austere structures to curb spending.
The OBBBA introduces sweeping changes to Medicaid eligibility, marketplace verification, and affordability mechanisms. Chaudhary warned that these reforms will increase the frequency with which patients cycle on and off coverage, creating uncertainty around adherence and complicating manufacturers’ forecasting models. Additionally, concerns about Medicare Part A’s trust fund solvency may drive Congress to seek rapid, high‑yield cost offsets, with drug pricing likely to be a primary lever.
MFN pricing, originally tied to government programs, is resurfacing as a broader market pressure. PBMs may begin to reference international prices when negotiating commercial contracts, compressing the U.S. pricing corridor. Manufacturers must weigh the trade‑offs of low‑price launches (which could trigger MFN tail risk) against high‑price launches (which may accelerate payer‑driven utilization controls).
The Asembia AXS26 Summit underscored that U.S. drug‑pricing policy is no longer a slow‑moving backdrop but an active driver of market dynamics. As the Inflation Reduction Act, MFN pressures, and the OBBBA converge, payers are tightening utilization management at an unprecedented pace, and manufacturers must adopt more proactive, data‑driven strategies to navigate the emerging volatility. The summit’s insights suggest that the next few years will demand heightened agility, continuous policy engagement, and integrated global‑U.S. launch planning to sustain the commercial viability of high‑cost specialty therapies.
